Jens Eckstein joined TVM Capital in 2004 and is a general partner in the firm’s life sciences practice, where he focuses on earlier-stage investments. He is a member of the Board of Directors of CoNCERT Pharmaceuticals, Magen Biosciences, and Ascent Therapeutics, and served as an Advisor to Sirtris Pharmaceuticals.
As director, Lead Discovery and Research IT, at Enanta Pharmaceuticals, he directed the company's lead discovery and knowledge management programs for novel therapeutics in hepatitis, asthma, psoriasis, and other autoimmune disorders. Prior to joining Enanta, Dr. Eckstein managed research groups in biochemistry, structural biology, and computational chemistry at Mitotix (now GPC-Biotech).
Dr. Eckstein earned his doctorate, summa cum laude, in biological chemistry at the University of Konstanz and Harvard University. He was a postdoctoral fellow at the University of California in San Francisco and is an alumnus of the Kauffman Fellows Program. The author of more than 20 scientific publications, Dr. Eckstein also holds several issued and pending patents. He is managing editor of Frontiers in Bioscience “Current Topics in Lead Discovery” and serves as an editorial board advisor for IDrugs. Dr. Eckstein is also an Advisor to the Alzheimer Research Forum (ARF) and a founding member of the Cure Dystonia Initiative Advisory Council (CDIAC).
Yes, the mood has undoubtedly improved in comparison to last year’s gathering of the healthcare investment community around the “old clock” at Union Square in San Francisco. But given the overall... Read more »
I spent an enlightening week in Tokyo earlier this month participating in the Kauffman Fellows Japan Summit. This summit was the brainchild of three visionary Kauffman Fellows who are on a... Read more »
Where should any financial technology startup live? We’re here to urge you to look no further, and seriously consider Boston. Boston is and will remain the perfect home for FinTech startups today and for years to come. Read on to learn why we’re so confident.